Pathogenesis, Diagnosis and Treatment of Hematologic Malignancies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 129
Special Issue Editor
Interests: AML; core binding factor AML; novel agents; bone marrow microenviroment; HSCT
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematologic malignancies represent a heterogeneous group of diseases that can have overlapping clinical manifestations, and their successful and optimal management relies on early and accurate diagnosis. Historically, hematologic malignancies played a role in the pioneering use of genetic analyses for diagnoses, prognoses, and therapeutic decision-making. Furthermore, the precise definition of the pathogenesis (thanks to advanced molecular techniques) has allowed us to understand the biologic basis of these diseases, ultimately leading to the development of several targeted therapies. Future research should focus on increasingly defining the genetic pathways with the aim of identifying and validating new therapeutic targets and rapidly translating them into clinical trials. In the present Special Issue, we invite authors to submit original research papers and reviews on how increasingly in-depth knowledge of the pathogenesis, diagnosis, and ultimately treatment of hematologic malignancies may improve patient outcomes.
Dr. Michele Gottardi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematologic malignancies
- pathogenesis
- diagnosis
- treatment
- targeted therapy
- molecular research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
